vs

Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Caledonia Mining Corp Plc is the larger business by last-quarter revenue ($46.9M vs $37.2M, roughly 1.3× Organogenesis Holdings Inc.). On growth, Caledonia Mining Corp Plc posted the faster year-over-year revenue change (13.8% vs -57.1%). Over the past eight quarters, Caledonia Mining Corp Plc's revenue compounded faster (17.1% CAGR vs -46.5%).

Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CMCL vs ORGO — Head-to-Head

Bigger by revenue
CMCL
CMCL
1.3× larger
CMCL
$46.9M
$37.2M
ORGO
Growing faster (revenue YoY)
CMCL
CMCL
+70.9% gap
CMCL
13.8%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CMCL
CMCL
Annualised
CMCL
17.1%
-46.5%
ORGO

Income Statement — Q3 FY2024 vs Q1 FY2026

Metric
CMCL
CMCL
ORGO
ORGO
Revenue
$46.9M
$37.2M
Net Profit
$3.3M
Gross Margin
41.2%
30.8%
Operating Margin
18.6%
-185.1%
Net Margin
7.0%
Revenue YoY
13.8%
-57.1%
Net Profit YoY
-33.3%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCL
CMCL
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$225.6M
Q3 25
$150.9M
Q2 25
$101.0M
Q1 25
$86.7M
Q4 24
$126.7M
Q3 24
$46.9M
$115.2M
Q2 24
$50.1M
$130.2M
Net Profit
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$21.6M
Q2 25
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$3.3M
$12.3M
Q2 24
$10.2M
$-17.0M
Gross Margin
CMCL
CMCL
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
41.2%
76.7%
Q2 24
45.8%
77.6%
Operating Margin
CMCL
CMCL
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
18.6%
5.4%
Q2 24
32.2%
-10.7%
Net Margin
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
14.3%
Q2 25
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
7.0%
10.7%
Q2 24
20.3%
-13.1%
EPS (diluted)
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.13
$0.09
Q2 24
$0.42
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCL
CMCL
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$7.2M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$231.0M
Total Assets
$339.7M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCL
CMCL
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$7.2M
$94.3M
Q2 24
$15.4M
$89.9M
Total Debt
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
$300.1M
Q3 25
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$231.0M
$278.5M
Q2 24
$231.1M
$263.5M
Total Assets
CMCL
CMCL
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$598.7M
Q3 25
$509.8M
Q2 25
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$339.7M
$446.3M
Q2 24
$338.5M
$443.2M
Debt / Equity
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCL
CMCL
ORGO
ORGO
Operating Cash FlowLast quarter
$4.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
$39.4M
Q3 25
$3.1M
Q2 25
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$4.6M
$8.7M
Q2 24
$19.1M
$4.7M
Free Cash Flow
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
CMCL
CMCL
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
1.40×
0.71×
Q2 24
1.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons